Clinical Trials Logo

Treatment Efficacy clinical trials

View clinical trials related to Treatment Efficacy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06221722 Recruiting - Clinical trials for Constipation - Functional

Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation

Start date: November 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to identify the characteristics of brain functional connectivity in refractory constipation and fluoxetine-sensitive patients. The main questions it aims to answer are: - Investigating the alterations in brain functional connectivity in patients with refractory constipation and fluoxetine-sensitive patients - Assessing the predictive value of brain functional connectivity regarding the efficacy of fluoxetine and standard protocol treatments for constipation. Participants will receive: - Standard physiological and psychological assessments of constipation - BOLD-fMRI tests - Standard protocol and fluoxetine treatment If there is a comparison group: Researchers will compare: Refractory group/Fluoxetine sensitive group to see the specific brain alterations.

NCT ID: NCT05813951 Recruiting - Treatment Efficacy Clinical Trials

Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock

Start date: December 2, 2022
Phase: N/A
Study type: Interventional

The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU

NCT ID: NCT04508803 Recruiting - Treatment Efficacy Clinical Trials

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

CHANGEABLE
Start date: September 14, 2020
Phase: Phase 2
Study type: Interventional

A number of anti-PD-1/L1 monoclonal antibodies have been approved for the treatment of various advanced tumors in the world, and many studies on anti-PD-1 /L1 monoclonal antibodies for breast cancer are also being carried out. HX008 (Taizhou Hanzhong Biomedical Co., Ltd.China) combined gemcitabine and cisplatin (GP) regimen for first-line treatment of advanced triple negative breast cancer has been shown good efficacy. On the other hand,HRD as the target of PARP inhibitor therapy in the treatment of breast cancer has a broad prospect, In HRD tumor patients, the use of PARPi can make obstacles of DNA damage repair(DDR), accumulation of DNA damage, thus promote the apoptosis of tumor cells. Several PARPi have been approved worldwide (including Olaparib, Rucaparib, Niraparib, Talazoparib, Veliparib) for the treatment of ovarian and/or breast cancer. Theoretically, PARPi and anti-PD-1 monoclonal antibody can play a synergistic mechanism. In this study, HX008 combined with Niraparib is designed to treat metastatic breast cancer patients with DDR gene (BRCA1/2, PALB2, CHEK2, ATM, ATR, BAP1, BARD1, BLM, BRIP1, CHEK1, CDK12, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCM, MRE11A, NBN, PTEN, RAD50, RAD51C, RAD51D, WRN) pathogenic/suspected pathogenic germline mutation, so as to explore the possibility of more combined therapy for breast cancer to achieve better therapeutic effect.